Previous 10 | Next 10 |
2024-02-08 11:37:46 ET More on Agios Pharmaceuticals, AIM ImmunoTech, etc. CVS Health Corporation (CVS) Q4 2023 Earnings Call Transcript CVS Health FY23 Earnings: Downgrades Inevitable, Long Term Outlook In The Balance CVS Health Corporation 2023 Q4 - Results - Earni...
2024-02-07 06:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 15, 2024, at 8:00 a.m...
2024-01-08 08:00:00 ET Summary Agios Pharmaceuticals, Inc. announced positive data from its Thalassemia trial in non-transfusion dependent patients. The company plans to file NDAs based on the trial results by the end of 2024, with potential approval in 2025. Agios is expected...
– Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in Non-Transfusion-Dependent Thalassemia – – Company Expects Four Additional Phase 3 Readouts by the End of 2025,...
2024-01-05 06:40:30 ET Summary Agios Pharmaceuticals completed its IPO in 2013 and sold its oncology portfolio for $1.8bn in 2021. Its stock price is down 50% across a 5-year period. The company's focus is now on mitapivat, which has been approved for hemolytic anemia and is being...
2024-01-03 13:51:32 ET More on Agios Pharmaceuticals, bluebird bio, etc. Crispr Therapeutics Is Overvalued (Rating Downgrade) bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market...
2024-01-03 07:01:21 ET Agios Pharmaceuticals ( NASDAQ: AGIO ) shares rose ~33% premarket on Wednesday after a global late-stage trial of mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia achieved its primary endpoint of hemoglobin response. Result...
–Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved for Key Secondary Endpoints of Change From Baseline in Both FACIT-Fatigue Score and Hemoglobin Concentration &...
News, Short Squeeze, Breakout and More Instantly...
Agios Pharmaceuticals Inc. Company Name:
AGIO Stock Symbol:
NASDAQ Market:
Agios Pharmaceuticals Inc. Website:
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation ...
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the BofA Securities 2024 Health Care Conference on T...
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation ...